Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes.

Objective: This study assessed the feasibility of safely achieving target glycated hemoglobin (A1C) of < or =7% by intensifying structured insulin titration regimens using inhaled human insulin (Exubera [EXU] [Pfizer Inc., New York, NY] [insulin human (recombinant DNA origin)] inhalation powder) in patients with type 2 diabetes inadequately controlled on combination oral antidiabetes agents (OADs).

Methods: In a randomized, open-label, parallel, 24-week multicenter trial, 107 type 2 diabetes patients with mean baseline A1C of 8.

Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.

Background: The objective was to compare the effects on glycemia of adding either inhaled human insulin (Exubera [EXU] [insulin human (recombinant DNA origin) inhalational powder]) or subcutaneous insulin glargine (GLA) to the treatment regimens of patients with type 2 diabetes uncontrolled with oral antidiabetic drugs.

Methods: Forty patients were randomized to receive either EXU three times daily prior to meals or subcutaneous GLA once daily in a crossover design. Interstitial glucose concentrations were monitored using a continuous glucose monitoring system (CGMS) for the final 72-h period of 8 treatment days.